H. Lundbeck A/S — Biomedical Watch V2

Traitements14programmes

Essais10liés

Publications10liées

SourceDBlocale

Traitements

14

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
EptinezumabMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.	Migraine	Phase 3	Traitement symptomatique	United States, Argentina, Canada, Italy, Mexico, Poland, Portugal, Serbia, …	À vérifier
IdalopirdineTo establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).	Alzheimer	Phase 3	Traitement symptomatique	United States, Argentina, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, …	À vérifier
Lu AF28996The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.	Parkinson	Phase 2	À vérifier	United States	À vérifier
Lu AG09222The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.	Migraine	Phase 2	À vérifier	United States, Bulgaria, Czechia, Denmark, France, Georgia, Germany, Hungary, …	À vérifier
IdalopirdineTo establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).	Alzheimer	Phase 3	Traitement symptomatique	United States, Argentina, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Italy, Poland, Romania, South Africa, Spain, Ukraine	À vérifier
Lu AF28996The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.	Parkinson	Phase 1	À vérifier	China	À vérifier
EptinezumabMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.	Migraine	Phase 3	Traitement symptomatique	Canada	À vérifier
EptinezumabMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.	Migraine	Phase 3	Traitement symptomatique	United States, Argentina, Canada, Italy, Mexico, Poland, Portugal, Serbia, Spain, Turkey (Türkiye), United Kingdom	À vérifier
Lu AG09222The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.	Migraine	Phase 2	À vérifier	United States, Bulgaria, Czechia, Denmark, France, Georgia, Germany, Hungary, Japan, Lithuania, Poland, Romania, Slovakia, Spain	À vérifier
EptinezumabMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.	Migraine	Phase 3	Traitement symptomatique	United States, Argentina, Canada, Italy, Mexico, Poland, Portugal, Serbia, Spain, Turkey (Türkiye), United Kingdom	À vérifier
EptinezumabMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.	Migraine	Phase 3	Traitement symptomatique	United States, Argentina, Canada, Italy, Mexico, Poland, Portugal, Serbia, Spain, Turkey (Türkiye), United Kingdom	À vérifier
EptinezumabMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.	Migraine	Non applicable	Traitement symptomatique	Denmark	À vérifier
EptinezumabMost individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting \> 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.	Migraine	Phase 4	Traitement symptomatique	United States	À vérifier
Lu AF28996The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.	Parkinson	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

10

Molécule	Indication / population	Phase	NCT	Titre	Statut
Lu AF28996	Parkinson	Phase 2	NCT07514858	DARE2 — A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations	RECRUITING
Eptinezumab	Migraine	Phase 4	NCT06701526	A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications	COMPLETED
Eptinezumab	Migraine	Non applicable	NCT05635604	Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.	COMPLETED
Eptinezumab	Migraine	Phase 3	NCT05897320	PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine	RECRUITING
Eptinezumab	Migraine	Phase 3	NCT05164172	REJOIN — A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine	RECRUITING
Lu AG09222	Migraine	Phase 2	NCT06323928	PROCEED — A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments	COMPLETED
Eptinezumab	Migraine	Phase 3	NCT04965675	PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine	RECRUITING
Eptinezumab	Migraine	Phase 3	NCT07191145	Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)	NOT_YET_RECRUITING
Lu AF28996	Parkinson	Phase 1	NCT07513441	A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)	RECRUITING
Idalopirdine	Alzheimer	Phase 3	NCT01955161	Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil	COMPLETED

Publications

10

Molécule	Indication / population	Titre	Journal	Date
Lu AG09222		Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention.	Expert opinion on emerging drugs
Eptinezumab		Needs-based epilepsy follow-up: seizure control, treatment adherence and patient care.	Epilepsy & behavior : E&B
Idalopirdine		Novel difluoromethyl-containing 1-((4-methoxy-3-(piperazin-1-yl)phenyl)sulfonyl)-1H-indole scaffold as potent 5-HTR antagonists: Design, synthesis, biological evaluation, and early in vivo cognition-enhancing studies.	Bioorganic & medicinal chemistry
Lu AF28996		Accurate measurement of longitudinal paramagnetic relaxation enhancement through division after subtraction.	Magnetic resonance letters
Lu AF28996		Corrigendum to "Enhancing myrcene biosynthesis in yeast through nuclear compartmentalization" [Synth Syst Biotechnol 15 (2027) 105-112].	Synthetic and systems biotechnology
Lu AF28996		Metabolic engineering of for efficient production of d-phenylglycine.	Synthetic and systems biotechnology
Lu AF28996		Zinc cadmium sulfide nanocrystals prepared in PAM water-soluble nanoreactors and their photocatalytic performance in photodegradation.	Nanotechnology
Lu AF28996		Association between temporal trajectories of inflammatory markers and prognosis in ischemic stroke.	Frontiers in neurology
Idalopirdine		Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders.	Biomolecules
Idalopirdine		Design, ADMET Screening, Prime MM-GBSA Binding Free Energy Calculation and MD Simulation of Some Novel Phenothiazines as 5HTR Antagonists Targeting Alzheimer's Disease.	Current computer-aided drug design